Evidence map›Paper›PMID 35086631›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2022

Fluoroquinolone preventive therapy for children exposed to MDR-TB.

T Gureva, A Turkova, E Yablokova, P Smirnova, O Sveshnikova, O Zolotaya, E Nikishova, E Heldal, S Hinderaker, J A Seddon and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Open veterinary journal · 2025
    Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

T GurevaNorthern State Medical University, Arkhangelsk, Russian Federation.
A TurkovaMRC Clinical Trials Unit at University College London, Institute of Clinical Trials &Methodology, London, UK.
E YablokovaNorthern State Medical University, Arkhangelsk, Russian Federation.
P SmirnovaArkhangelsk Clinical Antituberculosis Dispensary, Arkhangelsk, Russian Federation.
O SveshnikovaArkhangelsk Clinical Antituberculosis Dispensary, Arkhangelsk, Russian Federation.
O ZolotayaArkhangelsk Clinical Antituberculosis Dispensary, Arkhangelsk, Russian Federation.
E NikishovaNorthern State Medical University, Arkhangelsk, Russian Federation.
E HeldalHeart and Lung Patient Organization International, Oslo, Norway.
S HinderakerUniversity of Bergen, Bergen, Norway.
J A SeddonImperial College London, London, UK.
A MariandyshevNorthern State Medical University, Arkhangelsk, Russian Federation, Northern Arctic Federal University, Arkhangelsk, Russian Federation.

Funding

Medical Research Council MC_UU_00004/04Medical Research Council MR/R007942/1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

FluoroquinolonesTuberculosis, Multidrug-ResistantAntitubercular AgentsChildHumansAntitubercular AgentsFluoroquinolones

Identifiers

PMID35086631
PMCPMC8802561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.